Karyopharm Therapeutics

357 articles about Karyopharm Therapeutics

• Karyopharm To Present Data from Phase 1 Study of Selinexor in Patients with Treatment-Naïve Myelofibrosis at AACR and to Host Investor Webcast on April 18th

  4/14/2023

  Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will present updated data from the Phase 1 study evaluating the safety and efficacy of once-weekly selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis (NCT04562389) at the American Association for Cancer Research (AACR) Annual Meeting 2023.

• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 03, 2023

  4/3/2023

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 221,900 restricted stock units to thirteen newly-hired employees.

• Karyopharm Announces Updated Selinexor Data in Patients with Treatment-Naïve Myelofibrosis to be Presented at AACR 2023

  3/14/2023

  Karyopharm Therapeutics Inc. (Nasdaq: KPTI) today announced that results from its Phase 1 study evaluating the safety and efficacy of once-weekly selinexor in combination with standard dose ruxolitinib in patients with treatment-naïve myelofibrosis (NCT04562389) have been selected for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, Florida.

• Karyopharm to Participate at Barclays Global Healthcare Conference

  3/8/2023

  Karyopharm Therapeutics Inc. today announced that the Company's senior management team will participate at the Barclays Global Healthcare Conference in a fireside chat on Wednesday, March 15 at 4:35 p.m. ET.

• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 01, 2023

  3/1/2023

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 111,250 restricted stock units to eight newly-hired employees.

• Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO®

  2/21/2023

  Karyopharm Therapeutics Inc. and the Menarini Group ("Menarini") today announced that the United Kingdom's (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has granted full Marketing Authorization for NEXPOVIO.

• Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

  2/15/2023

  Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2022.

• Karyopharm to Present at SVB Securities Global Biopharma Conference

  2/9/2023

  Karyopharm Therapeutics Inc. today announced that the Company's senior management team will participate at the virtual SVB Securities Global Biopharma Conference in a fireside chat on Thursday, February 16 at 11:20 a.m. ET.

• Karyopharm to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023

  2/8/2023

  Karyopharm Therapeutics Inc. today announced it will report fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023.

• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2023

  2/1/2023

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 113,250 restricted stock units to ten newly-hired employees.

• Foundation Medicine Announces Collaboration with Karyopharm Therapeutics to Develop FoundationOne®CDx as a Companion Diagnostic for XPOVIO® (selinexor)

  1/10/2023

  Foundation Medicine Announces Collaboration with Karyopharm Therapeutics to Develop FoundationOne ® CDx as a Companion Diagnostic for XPOVIO® (selinexor).

• Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives

  1/9/2023

  Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2022 total revenue and U.S.

• Karyopharm to Present at 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Karyopharm Therapeutics Inc. (Nasdaq: KPTI) today announced that the Company's senior management team will participate at the 41st Annual J.P. Morgan Healthcare Conference in a podium presentation on Wednesday, January 11 at 10:30 a.m. PT, followed by a question-and-answer breakout session at 10:50 a.m. PT.

• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2023

  1/3/2023

  Karyopharm Therapeutics Inc. announced that the Company granted stock options to purchase an aggregate of 24,300 shares of Karyopharm's common stock and an aggregate of 16,600 restricted stock units to four newly-hired employees.

• Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022

  12/12/2022

  Karyopharm Therapeutics Inc. today announced updated results from the Phase 1 portion of its study evaluating the safety and efficacy of once-weekly selinexor in combination with standard dose ruxolitinib in patients with treatment-naïve myelofibrosis (NCT04562389).

• Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Naïve Myelofibrosis

  12/5/2022

  Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will host a webcast to discuss the updated results from the Phase 1 open-label, dose-escalation study evaluating selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis at the 64th American Society of Hematology (ASH) 2022 Annual Meeting and Exposition.

• Karyopharm Announces $165 Million Private Placement

  12/5/2022

  Karyopharm Therapeutics Inc. announced that it has entered into a securities purchase agreement with certain institutional investors for a private placement that is expected to result in gross proceeds of approximately $165 million before deducting any offering related expenses.

• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 01, 2022

  12/1/2022

  Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted stock options to purchase an aggregate of 6,100 shares of Karyopharm's common stock and an aggregate of 4,200 restricted stock units to two newly-hired employees.

• Karyopharm to Participate at Upcoming Investor Conferences

  11/8/2022

  Karyopharm Therapeutics Inc. , today announced that the Company's senior management team will participate in the following investor conferences in November.

• Karyopharm Announces New Selinexor Data in Myelofibrosis and Multiple Myeloma to be Presented at ASH 2022

  11/3/2022

  Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that two abstracts detailing new selinexor data have been selected for poster presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 10-13, 2022.